CN104262255A - 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法 - Google Patents

一种不对称催化合成γ-硝基吡唑酰胺化合物的方法 Download PDF

Info

Publication number
CN104262255A
CN104262255A CN201410486209.3A CN201410486209A CN104262255A CN 104262255 A CN104262255 A CN 104262255A CN 201410486209 A CN201410486209 A CN 201410486209A CN 104262255 A CN104262255 A CN 104262255A
Authority
CN
China
Prior art keywords
amide compound
otf
compound
pyrazole amide
trifluoromethanesulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410486209.3A
Other languages
English (en)
Inventor
冯小明
姚乾
刘小华
林丽丽
张宇恒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Original Assignee
Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University filed Critical Sichuan University
Priority to CN201410486209.3A priority Critical patent/CN104262255A/zh
Publication of CN104262255A publication Critical patent/CN104262255A/zh
Priority to CN201510075076.5A priority patent/CN105985292B/zh
Priority to CN201510291876.0A priority patent/CN105418502B/zh
Priority to US15/511,243 priority patent/US10464899B2/en
Priority to JP2017512956A priority patent/JP2017530956A/ja
Priority to PCT/CN2015/081341 priority patent/WO2016045415A1/zh
Priority to EP15844037.0A priority patent/EP3199525A4/en
Priority to US15/511,244 priority patent/US9796675B1/en
Priority to EP15844676.5A priority patent/EP3199526A4/en
Priority to PCT/CN2015/081422 priority patent/WO2016045416A1/zh
Priority to JP2017513185A priority patent/JP2017529343A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/53—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种不对称催化合成γ-硝基吡唑酰胺化合物的方法，采用硝基烷烃和α,β-不饱和吡唑酰胺为原料，手性氧化胺与稀土金属化合物形成的络合物为催化剂，

Description

一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
技术领域
本发明涉及手性氧化胺-稀土金属络合物催化α,β-不饱和吡唑酰胺与硝基烷烃的不对称Michael加成反应合成γ-硝基吡唑酰胺的方法。
背景技术
γ-硝基吡唑酰胺化合物在有机合成中占有很重要的地位，它不但可以在碱的催化下与甲醇发生甲酯化反应，操作简单，合成效率高，还可以通过简单的化学反应转化为γ-氨基酸、2-吡啶酮以及2-吡咯烷酮等具有生物活性的化合物。目前已有一些不对称催化合成γ-硝基吡唑酰胺的报道。
Carlos F.Barbas III等利用硫脲衍生物XIV为手性催化剂，氯仿为溶剂，在-20℃下实现了下列硝基烯与吡唑酰胺的不对称Michael加成反应，产物可获得34％-99％的收率、10:1->20:1的d.r值(d.r值：含有两个及以上手性中心的化合物的非对映选择性)和78％-97％的ee值(Angew.Chem.Int.Ed.2012,51,5381)。
Long Lu等利用硫脲衍生物2d为手性催化剂，甲苯为溶剂，在室温下实现了下列硝基烷烃与三氟甲基取代的吡唑酰胺的不对称Michael加成反应，产物可获得71％-91％的收率、4.4:1–9.9:1的d.r值(d.r值：含有两个及以上手性中心的化合物的非对映选择性)和80％-93％的ee值(ACS Catal.2013,3,502)。
Shuji Kanemasa等利用R,R-DBFOX/Ph*Ni(ClO4)2*3H2O(A)和2,2,6,6-tetramethylpiperidine(TMP)作为组合催化剂，硝基甲烷与四氢呋喃(v/v＝1/1)为混合溶剂，在-20℃至室温下实现了下列硝基甲烷对不饱和吡唑酰胺的不对称Michael加成反应，产物可获得39％-97％的收率和77％-97％的ee值(J.Am.Chem.Soc.2002,124,13394)。
综上所述，Carlos F.Barbas III的催化反应体系中，反应须在-20℃进行，会耗费很多能量；Long Lu的催化反应体系中，α,β-不饱和酰胺扩展的底物都是端位有三氟甲基取代的，限制比较大；Shuji Kanemasa的催化反应体系中，反应前需要在-78℃活化，并且扩展的16个底物中，有11个底物的反应温度为-20℃，3个底物需要0℃，仅仅只有两个底物可以在室温下反应，有11个底物的反应时间需要96h，其中有6个底物反应时间需要168h，并且收率也并不理想，反应完成后需先用饱和氯化铵洗涤产品后才柱层析分离纯化，反应条件苛刻，操作复杂，硝基甲烷的用量太大(0.1mmolα,β-不饱和吡唑酰胺化合物需要用9.1mmol硝基甲烷)，最重要的是所得的反应结果并不好。所以一种高效、操作简单、节约能源并利于环境的方法亟需被发展。
发明内容
本发明的目的是发展不对称催化α,β-不饱和吡唑酰胺化合物与硝基烷烃的Michael加成反应，提供一种高效、操作简单、节约能源并利于环境的合成γ-硝基吡唑酰胺化合物的方法。
本发明的方案是：一种不对称催化合成γ-硝基吡唑酰胺化合物的方法，其特征在于以硝基烷烃和α,β-不饱和吡唑酰胺为原料，手性氧化胺与稀土金属化合物形成的络合物为催化剂，分子筛为添加剂，二氯甲烷为溶剂，于25-50℃，常压下反应12-120h，TLC检测反应，硅胶柱层析分离，得手性γ-硝基吡唑酰胺化合物，其中：
硝基烷烃的结构为RCH2NO2，R＝H,CH3,Et,Bn；
α,β-不饱和吡唑酰胺化合物的结构为：
R1＝C6H5,4-FC6H4,4-ClC6H4,4-BrC6H4,4-MeC6H4,4-MeOC6H4,3-BrC6H4,3-MeC6H4,2-BrC6H4,2-MeOC6H4,3,4–Cl2C6H3,3,4-(MeO)2C6H3,2-Furyl,2-Thienyl,CH3,Pr,Pent,iBu,EtO,EtOOC；R2＝CH3,Ph；R3＝H,Cl,Br,I；
手性氧化胺配体的结构为：
n＝1,2；R＝Ph-,2,6-Me2C6H3-,2,6-Et2C6H3-,2,6-iPr2C6H3-,Ph2CH-；
稀土金属化合物为：三氟甲磺酸钆[Gd(OTf)3]、三氟甲磺酸钪[Sc(OTf)3]、三氟甲磺酸钬[Ho(OTf)3]、三氟甲磺酸镱[Yb(OTf)3]、三氟甲磺酸铒[Er(OTf)3]、三氟甲磺酸钇[Y(OTf)3]；
硝基烷烃与α,β-不饱和吡唑酰胺化合物的摩尔比是1.86:1-55.8:1,最佳摩尔比是9.3:1。
反应的最佳催化剂是手性氧化胺L6(n＝2，R＝2,6-iPr2C6H3-)与三氟甲磺酸钆[Gd(OTf)3]形成的络合物，手性氧化胺与稀土金属化合物的摩尔比为0.8:1.0-1.5:1.0,最佳摩尔比是1.2:1.0；
分子筛450℃下活化3小时，0.1mmol的α,β-不饱和吡唑酰胺对应的分子筛量为10-100mg；
二氯甲烷经GaH2回流干燥处理，0.1mmol的α,β-不饱和吡唑酰胺对应的量为6.2mmol；
反应温度为30℃；
反应时间为72-96h。
与背景技术相比，本发明具有如下突出优势：
1.操作简便，催化剂不需要活化，产物易与催化剂、添加剂、原料分离。
2.反应转化率和对映选择性高，反应收率高达99％，对映选择性高达99％ee。
3.反应体系简单清洁，无需酸、碱添加剂。
4.反应条件温和，常压30℃下反应。
5.硝基烷烃的用量较少，节约原料。
具体实施方式
实施例1：手性氧化胺与稀土金属络合物催化不对称α,β-不饱和吡唑酰胺与硝基烷烃的Michael加成反应
在反应容器中加入稀土金属化合物(序号1-11:0.01mmol,序号12-16:0.0075mmol)、手性氧化胺配体(序号1-11:0.012mmol,序号12-16:0.009mmol)、α,β-不饱和吡唑酰胺1a(0.1mmol)、分子筛30mg、搅拌子，置换氮气3次后加入二氯甲烷(6.2mmol)、硝基甲烷(序号1-11:5.6mmol,序号12-16:0.93mmol)，于25-50℃搅拌12-120h。TLC监测反应。柱层析分离纯化，产物的对映体过量用高效液相色谱(Daicel chiralcel IE，V正己烷:V异丙醇＝90：10，流速1.0mL/min)测定，见表1。反应式和手性氧化胺配体结构如下：
表一.手性氧化胺与稀土金属络合物催化不对称α,β-不饱和吡唑酰胺和硝基甲烷的不对称Michael加成反应条件优化(n.d.：未检测)
实施例2：手性氧化胺L6-Gd(OTf)3络合物催化不对称α,β-不饱和吡唑酰胺与硝基烷烃的Michael加成反应
在反应容器中加入Gd(OTf)3(序号1-16,20-23,25-27:0.0075mmol,序号17-19,24:0.01mmol)、手性氧化胺L6(序号1-16,20-23,25-27:0.009mmol,序号17-19,24:0.012mmol)(手性氧化胺L6与三氟甲磺酸钆(Gd(OTf)3)的摩尔比为1.2:1.0)、α,β-不饱和酰胺(0.1mmol)、分子筛(序号1-16,20-27:30mg,序号18:100mg,序号17,19:60mg)、搅拌子，置换氮气3次后加入6.2mmol二氯甲烷和0.93mmol硝基烷烃，30℃下搅拌72h。柱层析分离纯化，产物的对映体过量用手性高效液相色谱测定，反应式如下：
反应结果见表2：(d.r:含有两个及以上手性中心的化合物的非对映选择性)
表2.手性氧化胺L6-Gd(OTf)3络合物催化不对称α,β-不饱和吡唑酰胺与硝基烷烃的Michael加成反应
序号 R,R1,R2,R3 收率(％) 对映选择性(％ee)
1 H,C6H5,CH3,H 99 99
2 H,4-FC6H4,CH3,H 99 99
3 H,4-ClC6H4,CH3,H 98 98
4 H,4-BrC6H4,CH3,H 96 98
5 H,4-MeC6H4,CH3,H 95 99
6 H,4-MeOC6H4,CH3,H 89 99
7 H,3-BrC6H4,CH3,H 98 98
8 H,3-MeC6H4,CH3,H 96 99
9 H,2-BrC6H4,CH3,H 99 99
10 H,2-MeOC6H4,CH3,H 99 99
11 H,3,4–Cl2C6H3,CH3,H 96 99
12 H,3,4-(MeO)2C6H3,CH3,H 83 99
13 H,2-Furyl,CH3,H 56 97
14 H,2-Thienyl,CH3,H 58 98
15 H,CH3,CH3,H 69 98
16 H,Pr,CH3,H 87 98
17 H,Pent,CH3,H 65 98
18 H,iBu,CH3,H 77 98
19 H,EtO,CH3,H 53 95
20 H,EtOOC,CH3,H 67 95
21 H,4-ClC6H4,CH3,Cl 94 99
22 H,4-ClC6H4,CH3,Br 96 99
23 H,4-ClC6H4,CH3,I 97 99
24 H,4-ClC6H4,C6H5,H 39 81
25 CH3,4-ClC6H4,CH3,H 94 98/98(d.r.1.6/1)
26 Et,4-ClC6H4,CH3,H 87 99/98(d.r.1.2/1)
27 PhCH2,4-ClC6H4,CH3,H 98 99/98(d.r.1.1/1)
实施例3：放大量实验1
在装有磁力搅拌装置的圆底烧瓶中，加入氧化胺配体L6(0.24mmol)、三氟甲磺酸钆(0.2mmol)、序号2中不饱和酰胺(0.976g，4mmol)、分子筛1.2g，抽换氮气3次，然后加入186mmol二氯甲烷、37.2mmol硝基甲烷，30℃下搅拌96h。硅胶柱层析分离，得到催化产物为白色固体，1.217g，收率：99％；利用高效液相色谱(Daicel chiralcel IE，V正己烷:V异 丙醇＝90：10，流速1.0mL/min)测定，得到产物的对映选择性ee值99％。
实施例4：放大量实验2
在装有磁力搅拌装置的圆底烧瓶中，加入氧化胺配体L6(0.36mmol)、三氟甲磺酸钆(0.3mmol)、序号3中不饱和酰胺(1.04g，4mmol)、分子筛1.2g，抽换氮气3次，然后加入186mmol二氯甲烷、37.2mmol硝基甲烷，30℃下搅拌72h。硅胶柱层析分离，得到催化产物为白色固体，1.278g，收率：99％；利用高效液相色谱(Daicel chiralcel IE，V正己烷:V异 丙醇＝90：10，流速1.0mL/min)测定，得到产物的对映选择性ee值98％。
实施例5：放大量实验3
在装有磁力搅拌装置的圆底烧瓶中，加入氧化胺配体L6(0.72mmol)、三氟甲磺酸钆(0.6mmol)、序号18中不饱和酰胺(1.236g，6mmol)、分子筛6.5g，抽换氮气3次，然后加入325.5mmol二氯甲烷、55.8mmol硝基甲烷，30℃下搅拌72h。硅胶柱层析分离，得到催化产物为无色液体，1.34g，收率：83％；利用高效液相色谱(Daicel chiralcel IE，V正己烷:V异丙醇＝90：10，流速1.0mL/min)测定，得到产物的对映选择性ee值99％。
γ-硝基吡唑酰胺化合物在合成中的应用：
实施例6：催化产物的酯化反应
催化反应完成后(起始α,β-不饱和吡唑酰胺为0.1mmol)，往盛有3b和3a反应液的试管中分别加入DBU(0.067mmol)和甲醇(2.5mmol),在室温下搅拌过夜。柱层析分离纯化，利用高效液相色谱分析(3a:Daicel chiralcel IB，V正己烷:V异丙醇＝90:10，流速1.0mL/min)、(3b:Daicel chiralcel IC，V正己烷:V异丙醇＝95:5，流速0.8mL/min)。结果如下：
5a和5b可以按照文献报道的方法合成药物分子，巴氯芬和帕罗西汀(Org.Lett.2012,14,1516)。
由于脂肪类的酯类化合物不便于检测和分离纯化，所以采取了分步的方式来完成酯化的过程：在反应容器中加入3t(46.2mg,0.173mmol，98％ee，)，然后依次加入7.8mmol二氯甲烷、DBU(0.1mmol)、甲醇(3.72mmol)，室温下搅拌5h。柱层析分离纯化，利用高效液相色谱分析(Daicel chiralcel IE，V正己烷:V异丙醇＝95:5，流速1.0mL/min)，产物收率95％，对映体选择性98％ee。结果如下：
实施例7：普瑞巴林的合成
中国科学院成都有机化学有限公司公布了消旋的5c转化为消旋的6c的方法。他们用的是雷尼镍-H2作为氢化试剂对5c进行了还原关环，以97％的收率得到6c，虽然结果很好，但是操作复杂，并且过程中用到雷尼镍、氢气这些危险的试剂(CN 102115449A.06,07,2011)。
在这里我们提供了下列由5c合成6c的方法：该法反应条件温和、操作简单、反应高效
在装有磁力搅拌装置的圆底烧瓶中，加入5c(68.82mg,0.34mmol)、NiCl2·6H2O(80.6mg,0.34mmol)、EtOH(33.9mmol)，然后置于冰浴中5分钟，然后慢慢加入NaBH4(140.9mg,3.74mmol)，反应溶液继续在冰浴下搅拌2小时。然后加入1mL乙醇淬灭反应，回到室温，往反应液中加入1mL 6mol/L的氢氧化钠溶液，继续搅拌1h。1h后，往反应液中加入2mol/L的盐酸溶液，调节PH值小于7，然后用二氯甲烷(4x 6mL)萃取，合并有机层，用无水硫酸钠干燥，接着抽滤旋干既得产物6c，收率：95％，利用高效液相色谱分析(Daicel chiralcelAD-H，V正己烷:V异丙醇＝96：4，流速1.0mL/min)，得到产物的对映选择性ee值97％。
化合物6c按照文献的报道(Tetrahedron,2011,67,636)，在6mol/L盐酸中，100℃下回流10小时，便可以以95％的收率拿到普瑞巴林的盐酸盐并且ee值得到保持。

Claims (11)

1.一种不对称催化合成γ-硝基吡唑酰胺化合物的方法，其特征在于：以α,β-不饱和吡唑酰胺和硝基烷烃为原料，手性氧化胺与稀土金属化合物形成的络合物为催化剂，分子筛为添加剂，二氯甲烷为溶剂，于25-50℃,常压下反应12-120h，得手性γ-硝基吡唑酰胺化合物，其中：硝基烷烃的结构为RCH2NO2,R＝H,CH3,Et,Bn；
α,β-不饱和吡唑酰胺的结构为：
R1＝C6H5,4-FC6H4,4-ClC6H4,4-BrC6H4,4-MeC6H4,4-MeOC6H4,3-BrC6H4,3-MeC6H4,2-BrC6H4,2-MeOC6H4,3,4–Cl2C6H3,3,4-(MeO)2C6H3,2-Furyl,2-Thienyl,CH3,Pr,Pent,iBu,EtO,EtOOC；R2＝CH3,Ph；R3＝H,Cl,Br,I；
手性氧化胺配体的结构为：
n＝1,2；R＝Ph-,2,6-Me2C6H3-,2,6-Et2C6H3-,2,6-iPr2C6H3-,Ph2CH-；
稀土金属化合物为：三氟甲磺酸钆[Gd(OTf)3]、三氟甲磺酸钪[Sc(OTf)3]、三氟甲磺酸钬[Ho(OTf)3]、三氟甲磺酸镱[Yb(OTf)3]、三氟甲磺酸铒[Er(OTf)3]、三氟甲磺酸钇[Y(OTf)3]；
硝基烷烃与α,β-不饱和吡唑酰胺化合物的摩尔比是1.86:1-55.8:1；
手性氧化胺与稀土金属化合物的摩尔比为0.8:1.0-1.5:1.0；
分子筛的量为:0.1mmol的α,β-不饱和吡唑酰胺需分子筛为10-100mg；
二氯甲烷与α,β-不饱和吡唑酰胺化合物的摩尔比为3.1:1.0-7.8:1.0。
2.按权利要求1所述的方法，其特征在于硝基烷烃与α,β-不饱和吡唑酰胺化合物的摩尔比为9.3:1。
3.按权利要求1所述的方法，其特征在于稀土金属化合物是三氟甲磺酸钆[Gd(OTf)3]。
4.按权利要求1所述的方法，其特征在于手性氧化胺配体是n＝2,R＝2,6-iPr2C6H3-。
5.按权利要求1所述的方法，其特征在于手性氧化胺配体和三氟甲磺酸钆[Gd(OTf)3]的摩尔比为1.2:1。
6.按权利要求1所述的方法，α,β-不饱和吡唑酰胺化合物与稀土金属化合物的摩尔比为20:1-10:1。
7.按权利要求1所述的方法，其特征在于0.1mmolα,β-不饱和吡唑酰胺化合物需要分子筛30-100mg。
8.按权利要求1所述的方法，其特征在于0.1mmolα,β-不饱和吡唑酰胺化合物需要二氯甲烷6.2mmol。
9.按权利要求1所述的方法，其特征在于分子筛须450℃活化3h，二氯甲烷需CaH2干燥回流1h。
10.按权利要求1所述的方法，其特征在于反应温度为30℃。
11.按权利要求10所述的方法，其特征在于反应时间为72-96h。
CN201410486209.3A 2014-09-22 2014-09-22 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法 Pending CN104262255A (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201410486209.3A CN104262255A (zh) 2014-09-22 2014-09-22 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
CN201510075076.5A CN105985292B (zh) 2014-09-22 2015-02-12 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
CN201510291876.0A CN105418502B (zh) 2014-09-22 2015-06-01 一种用于合成帕罗西汀的中间体及其制备方法和用途
EP15844037.0A EP3199525A4 (en) 2014-09-22 2015-06-12 Method for asymmetrically catalyzed synthesis of nitropyrazole amide compound
JP2017512956A JP2017530956A (ja) 2014-09-22 2015-06-12 ニトロピラゾールアミド化合物の不斉触媒合成方法
US15/511,243 US10464899B2 (en) 2014-09-22 2015-06-12 Asymmetrically catalyzed synthesis method of nitropyrazole amide compound
PCT/CN2015/081341 WO2016045415A1 (zh) 2014-09-22 2015-06-12 一种不对称催化合成硝基吡唑酰胺化合物的方法
US15/511,244 US9796675B1 (en) 2014-09-22 2015-06-15 Intermediate for synthesizing paroxetine, method for preparing the same, and uses thereof
EP15844676.5A EP3199526A4 (en) 2014-09-22 2015-06-15 Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof
PCT/CN2015/081422 WO2016045416A1 (zh) 2014-09-22 2015-06-15 一种用于合成帕罗西汀的中间体及其制备方法和用途
JP2017513185A JP2017529343A (ja) 2014-09-22 2015-06-15 パロキセチンを合成するための中間体およびその製造方法と用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410486209.3A CN104262255A (zh) 2014-09-22 2014-09-22 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法

Publications (1)

Publication Number Publication Date
CN104262255A true CN104262255A (zh) 2015-01-07

Family

ID=52153873

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410486209.3A Pending CN104262255A (zh) 2014-09-22 2014-09-22 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
CN201510075076.5A Active CN105985292B (zh) 2014-09-22 2015-02-12 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
CN201510291876.0A Active CN105418502B (zh) 2014-09-22 2015-06-01 一种用于合成帕罗西汀的中间体及其制备方法和用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510075076.5A Active CN105985292B (zh) 2014-09-22 2015-02-12 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
CN201510291876.0A Active CN105418502B (zh) 2014-09-22 2015-06-01 一种用于合成帕罗西汀的中间体及其制备方法和用途

Country Status (5)

Country Link
US (2) US10464899B2 (zh)
EP (2) EP3199525A4 (zh)
JP (2) JP2017530956A (zh)
CN (3) CN104262255A (zh)
WO (1) WO2016045416A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016045415A1 (zh) * 2014-09-22 2016-03-31 浙江九洲药业股份有限公司 一种不对称催化合成硝基吡唑酰胺化合物的方法
WO2016045416A1 (zh) * 2014-09-22 2016-03-31 浙江九洲药业股份有限公司 一种用于合成帕罗西汀的中间体及其制备方法和用途
CN106748949A (zh) * 2017-01-13 2017-05-31 厦门大学 一种合成α,β不饱和酰胺化合物的方法
CN112876328A (zh) * 2021-01-15 2021-06-01 四川大学 一种不对称催化合成γ-氰基酰胺化合物及采用该化合物手性药物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
WO2009005647A2 (en) * 2007-06-27 2009-01-08 Bioverdant, Inc. Compounds and process to prepare chiral intermediates for synthesis of paroxetine
CN102531825B (zh) * 2010-12-29 2014-04-23 中国科学院大连化学物理研究所 一种促进丙烷转化制芳烃的方法
CN102531815B (zh) * 2011-12-22 2014-04-16 四川大学 一种不对称催化α,β-不饱和羰基化合物环氧化反应方法
CN104262255A (zh) * 2014-09-22 2015-01-07 四川大学 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016045415A1 (zh) * 2014-09-22 2016-03-31 浙江九洲药业股份有限公司 一种不对称催化合成硝基吡唑酰胺化合物的方法
WO2016045416A1 (zh) * 2014-09-22 2016-03-31 浙江九洲药业股份有限公司 一种用于合成帕罗西汀的中间体及其制备方法和用途
CN105985292A (zh) * 2014-09-22 2016-10-05 浙江九洲药业股份有限公司 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
JP2017529343A (ja) * 2014-09-22 2017-10-05 浙江九洲▲藥▼▲業▼股▲ふぇん▼有限公司Ｚｈｅｊｉａｎｇ Ｊｉｕｚｈｏｕ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． パロキセチンを合成するための中間体およびその製造方法と用途
CN105985292B (zh) * 2014-09-22 2019-05-10 浙江九洲药业股份有限公司 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
CN106748949A (zh) * 2017-01-13 2017-05-31 厦门大学 一种合成α,β不饱和酰胺化合物的方法
CN106748949B (zh) * 2017-01-13 2019-04-09 厦门大学 一种合成α,β不饱和酰胺化合物的方法
CN112876328A (zh) * 2021-01-15 2021-06-01 四川大学 一种不对称催化合成γ-氰基酰胺化合物及采用该化合物手性药物的方法

Also Published As

Publication number Publication date
CN105418502B (zh) 2018-12-14
US20170291876A1 (en) 2017-10-12
JP2017530956A (ja) 2017-10-19
EP3199526A4 (en) 2018-02-14
EP3199526A1 (en) 2017-08-02
EP3199525A4 (en) 2018-02-14
US20170283380A1 (en) 2017-10-05
CN105985292A (zh) 2016-10-05
WO2016045416A1 (zh) 2016-03-31
US9796675B1 (en) 2017-10-24
CN105418502A (zh) 2016-03-23
US10464899B2 (en) 2019-11-05
EP3199525A1 (en) 2017-08-02
JP2017529343A (ja) 2017-10-05
CN105985292B (zh) 2019-05-10

Similar Documents

Publication Publication Date Title
Hamashima et al. Highly enantioselective fluorination reactions of β-ketoesters and β-ketophosphonates catalyzed by chiral palladium complexes
Newton et al. Catalytic enantioselective transformations involving C–H bond cleavage by transition-metal complexes
CN101116828B (zh) 手性吡啶双噁唑啉催化剂及制备方法和应用
Lectard et al. Recent advances in catalytic enantioselective fluorination reactions
CN104262255A (zh) 一种不对称催化合成γ-硝基吡唑酰胺化合物的方法
Pu et al. Doubly stereocontrolled asymmetric conjugate addition of acetylacetone to nitroolefins catalyzed by bifunctional tertiary amine–thiourea catalysts derived from both acyclic α-amino acids and carbohydrates
Shen et al. A mild and efficient cyanosilylation of ketones catalyzed by a Lewis acid–Lewis base bifunctional catalyst
CN101362100A (zh) 手性胺-(硫)脲双功能催化剂及其合成方法和应用
Nakayama et al. Asymmetric Morita–Baylis–Hillman reactions of 2-cyclohexen-1-one catalyzed by chiral biaryl-based bis (thiourea) organocatalysts
Kantam et al. Nanocrystalline copper (II) oxide catalyzed aza-Michael reaction and insertion of α-diazo compounds into N–H bonds of amines
Chen et al. Bifunctional AgOAc-catalyzed asymmetric reactions
Song et al. Nickel-Catalyzed Remote C (sp3)–N/O Bond Formation of Alkenes with Unactivated Amines and Alcohols
CN102850153B (zh) 一种催化α,β-不饱和烯酮及饱和酮的不对称还原反应方法
EP3045459B1 (en) Method for preparing intermediate compound of sitagliptin
Ye et al. Nickel (II)-catalyzed asymmetric alkylation of acyclic oxocarbenium ions with carboxylic acid derivatives
Shibatomi et al. Lewis acid-catalyzed asymmetric fluorinations of β-keto esters: dramatic improvement in enantioselectivity by changing the operation sequence
Tanimura et al. Asymmetric allylation reactions of aromatic aldehydes with allyltrichlorosilane catalyzed by chiral bisformamide-type organocatalysts
CN101892273B (zh) 固定化脂肪酶Lipozyme TLIM作为不对称Michael加成反应催化剂的应用
Liang et al. Total Syntheses of (+)-α-Allokainic Acid and (−)-2-epi-α-Allokainic Acid Employing Ketopinic Amide as a Chiral Auxiliary
CN109336924A (zh) 一种负载型Pd配合物催化卤代芳烃绿色氰基化的方法
WO2016045415A1 (zh) 一种不对称催化合成硝基吡唑酰胺化合物的方法
Handique et al. Reduction of α, β unsaturated carbonyl compounds by Ni2+–BH4−
Sui et al. Cu (II)‐Catalyzed Enantioselective Conjugate Reduction for the Synthesis of N‐Aryl β‐Amino Acid Esters
Zheng et al. Catalytic, Conjugate Reduction‐Aldol Addition Reaction of β′‐Oxoalkyl α, β‐Unsaturated Carboxylates
CN101906445A (zh) 2h-1-苯并吡喃-2-酮衍生物的合成方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: JIUZHOU PHARMACEUTICAL CO., LTD., ZHEJIANG

Free format text: FORMER OWNER: SICHUAN UNIVERSITY

Effective date: 20150129

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 610065 CHENGDU, SICHUAN PROVINCE TO: 318000 TAIZHOU, ZHEJIANG PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20150129

Address after: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 99

Applicant after: Jiuzhou Pharmaceutical Co., Ltd., Zhejiang

Address before: 610065 Wuhou District, Chengdu, South Ring Road, No. 1, No. 1, Sichuan

Applicant before: Sichuan University

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150107